Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ikonisys, a provider of next-generation, cell-based diagnostic solutions, has reported positive results from a clinical study conducted by a research group at the Weatherall Institute of Molecular Medicine at Oxford University, a laboratory supported by Cancer Research UK.
Subscribe to our email newsletter
The study validates the company’s CellOptics platform and proprietary digital microscope, the Ikoniscope, as a viable method for quickly and easily detecting and detailing circulating tumor cells (CTC) in the blood. The findings represent a significant milestone for screening and disease monitoring for a variety of cancers, including prostate, colorectal and ovarian.
The study demonstrates the importance of CTC detection in providing a new and effective approach to the overall management of cancer. The study analyzed blood samples from several patients with prostate, colorectal and ovarian cancer.
The blood samples were analyzed using the Ikoniscope, a fully-automated, fluorescence microscopy imaging system. CTCs were detected in 23 of 25 colorectal, 10 of 10 prostate and four of four ovarian cancer patients. Overall, study results show that CTCs could be used for early cancer screening, detection of recurrence and evaluation of response to therapy.
Petros Tsipouras, CEO and chairman of Ikonisys, said: “This new method of detecting CTCs shows great promise in our continuous quest to provide physicians and patients with early, accurate screening methods that ultimately enable personalized medical treatments.”